Literature DB >> 25818486

NADPH oxidases and cancer.

Krishnendu Roy1, Yongzhong Wu2, Jennifer L Meitzler2, Agnes Juhasz2, Han Liu1, Guojian Jiang2, Jiamo Lu2, Smitha Antony2, James H Doroshow1.   

Abstract

The mechanism by which reactive oxygen species (ROS) are produced by tumour cells remained incompletely understood until the discovery over the last 15 years of the family of NADPH oxidases (NOXs 1-5 and dual oxidases DUOX1/2) which are structural homologues of gp91phox, the major membrane-bound component of the respiratory burst oxidase of leucocytes. Knowledge of the roles of the NOX isoforms in cancer is rapidly expanding. Recent evidence suggests that both NOX1 and DUOX2 species produce ROS in the gastrointestinal tract as a result of chronic inflammatory stress; cytokine induction (by interferon-γ, tumour necrosis factor α, and interleukins IL-4 and IL-13) of NOX1 and DUOX2 may contribute to the development of colorectal and pancreatic carcinomas in patients with inflammatory bowel disease and chronic pancreatitis, respectively. NOX4 expression is increased in pre-malignant fibrotic states which may lead to carcinomas of the lung and liver. NOX5 is highly expressed in malignant melanomas, prostate cancer and Barrett's oesophagus-associated adenocarcinomas, and in the last it is related to chronic gastro-oesophageal reflux and inflammation. Over-expression of functional NOX proteins in many tissues helps to explain tissue injury and DNA damage from ROS that accompany pre-malignant conditions, as well as elucidating the potential mechanisms of NOX-related damage that contribute to both the initiation and the progression of a wide range of solid and haematopoietic malignancies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25818486     DOI: 10.1042/CS20140542

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  72 in total

Review 1.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

2.  Nuclear NADPH oxidase-4 associated with disease progression in renal cell carcinoma.

Authors:  Dharam Kaushik; Keith A Ashcraft; Hanzhang Wang; Karthigayan Shanmugasundaram; Pankil K Shah; Gabriela Gonzalez; Alia Nazarullah; Cooper B Tye; Michael A Liss; Deepak K Pruthi; Ahmed M Mansour; Wasim Chowdhury; Dean Bacich; Hao Zhang; Amanda L Watson; Karen Block; Denise O'Keefe; Ronald Rodriguez
Journal:  Transl Res       Date:  2020-05-31       Impact factor: 7.012

Review 3.  Insights into the role of the intestinal microbiota in colon cancer.

Authors:  Sofia Oke; Alberto Martin
Journal:  Therap Adv Gastroenterol       Date:  2017-02-01       Impact factor: 4.409

4.  Association between NADPH oxidase (NOX) and lung cancer: a systematic review and meta-analysis.

Authors:  Ming Han; Tianhui Zhang; Lei Yang; Zitong Wang; Junzhong Ruan; Xiujun Chang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

5.  Inhibiting the Activity of NADPH Oxidase in Cancer.

Authors:  Mariam M Konaté; Smitha Antony; James H Doroshow
Journal:  Antioxid Redox Signal       Date:  2020-04-17       Impact factor: 8.401

Review 6.  The Oxygen Paradox, the French Paradox, and age-related diseases.

Authors:  Joanna M S Davies; Josiane Cillard; Bertrand Friguet; Enrique Cadenas; Jean Cadet; Rachael Cayce; Andrew Fishmann; David Liao; Anne-Laure Bulteau; Frédéric Derbré; Amélie Rébillard; Steven Burstein; Etienne Hirsch; Robert A Kloner; Michael Jakowec; Giselle Petzinger; Delphine Sauce; Florian Sennlaub; Isabelle Limon; Fulvio Ursini; Matilde Maiorino; Christina Economides; Christian J Pike; Pinchas Cohen; Anne Negre Salvayre; Matthew R Halliday; Adam J Lundquist; Nicolaus A Jakowec; Fatima Mechta-Grigoriou; Mathias Mericskay; Jean Mariani; Zhenlin Li; David Huang; Ellsworth Grant; Henry J Forman; Caleb E Finch; Patrick Y Sun; Laura C D Pomatto; Onnik Agbulut; David Warburton; Christian Neri; Mustapha Rouis; Pierre Cillard; Jacqueline Capeau; Jean Rosenbaum; Kelvin J A Davies
Journal:  Geroscience       Date:  2017-12-21       Impact factor: 7.713

7.  p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.

Authors:  Dannah R Miller; Matthew A Ingersoll; Arpita Chatterjee; Brian Baker; Shashank Shrishrimal; Elizabeth A Kosmacek; Yuxiang Zhu; Pi-Wan Cheng; Rebecca E Oberley-Deegan; Ming-Fong Lin
Journal:  Free Radic Biol Med       Date:  2019-05-14       Impact factor: 7.376

8.  DR1 activation reduces the proliferation of vascular smooth muscle cells by JNK/c-Jun dependent increasing of Prx3.

Authors:  Junting Chen; Sa Shi; Xiaona Cai; Hongzhu Li; Lina Wang; Hong Li; Changqing Xu
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

9.  PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Authors:  Terry W Moody; Lingaku Lee; Tatiana Iordanskaia; Irene Ramos-Alvarez; Paola Moreno; Howard E Boudreau; Thomas L Leto; Robert T Jensen
Journal:  Peptides       Date:  2018-09-28       Impact factor: 3.750

Review 10.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.